- Home
- ADAP vs HBIO Comparison
ADAP vs HBIO Comparison
Compare ADAP & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- HBIO
- Stock Information
- Founded
- ADAP 2008
- HBIO 1901
- Country
- ADAP United Kingdom
- HBIO United States
- Employees
- ADAP N/A
- HBIO N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- ADAP Health Care
- HBIO Industrials
- Exchange
- ADAP Nasdaq
- HBIO Nasdaq
- Market Cap
- ADAP 21.3M
- HBIO 24.6M
- IPO Year
- ADAP 2015
- HBIO 2000
- Fundamental
- Price
- ADAP $0.07
- HBIO $0.44
- Analyst Decision
- ADAP Hold
- HBIO Buy
- Analyst Count
- ADAP 6
- HBIO 3
- Target Price
- ADAP $1.02
- HBIO $2.50
- AVG Volume (30 Days)
- ADAP 63.5M
- HBIO 457.4K
- Earning Date
- ADAP 11-12-2025
- HBIO 11-06-2025
- Dividend Yield
- ADAP N/A
- HBIO N/A
- EPS Growth
- ADAP N/A
- HBIO N/A
- EPS
- ADAP N/A
- HBIO N/A
- Revenue
- ADAP $65,084,999.00
- HBIO $88,750,000.00
- Revenue This Year
- ADAP N/A
- HBIO N/A
- Revenue Next Year
- ADAP $52.35
- HBIO $7.13
- P/E Ratio
- ADAP N/A
- HBIO N/A
- Revenue Growth
- ADAP N/A
- HBIO N/A
- 52 Week Low
- ADAP $0.04
- HBIO $0.28
- 52 Week High
- ADAP $1.12
- HBIO $3.04
- Technical
- Relative Strength Index (RSI)
- ADAP 44.99
- HBIO 40.70
- Support Level
- ADAP $0.06
- HBIO $0.49
- Resistance Level
- ADAP $0.07
- HBIO $0.47
- Average True Range (ATR)
- ADAP 0.01
- HBIO 0.03
- MACD
- ADAP 0.01
- HBIO -0.01
- Stochastic Oscillator
- ADAP 88.67
- HBIO 13.00
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.